Showing results (271-280 of 322) with videos related to
Sort By:
Pageof 33
Ugeskrift for Laeger|October 1, 2021
[Challenges in cancer treatment for the elderly]Marianne Ewertz, Sidse Ehmsen, Trine Lembrecht Jørgensen, et al.Plos One|October 3, 2012
GAGE cancer-germline antigens are recruited to the nuclear envelope by germ cell-less (GCL)Morten F Gjerstorff, Heike I Rösner, Christina B Pedersen, et al.Cancer Cell|December 27, 2024
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunityShijun Ma, Li-Teng Ong, Zemin Jiang, et al.Molecular Oncology|August 2, 2014
Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced settingAnieta M Sieuwerts, Maria B Lyng, Marion E Meijer-van Gelder, et al.Frontiers in Oncology|February 11, 2025
RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancerCharlotte K Kindt, Sidse Ehmsen, Sofie Traynor, et al.Molecular Oncology|November 4, 2014
Ectopic expression of cancer/testis antigen SSX2 induces DNA damage and promotes genomic instabilityKatrine B V Greve, Jonas N Lindgreen, Mikkel G Terp, et al.Cancer Cell|February 22, 2023
BQ.1.1, XBB.1, and XBB.1.5 neutralization after bivalent mRNA COVID-19 booster in patients with cancerSidse Ehmsen, Rune M Pedersen, Line L Bang, et al.Journal for Immunotherapy of Cancer|September 12, 2022
Targeting two distinct epitopes on human CD73 with a bispecific antibody improves anticancer activityOdd L Gammelgaard, Mikkel G Terp, Christian Renn, et al.Nature Communications|August 26, 2021
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancerCarla L Alves, Sidse Ehmsen, Mikkel G Terp, et al.Nature Communications|November 19, 2020
EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapyYi Bao, Gokce Oguz, Wee Chyan Lee, et al.Pageof 33